Prevention of Events with Angiotensin-Converting Enzyme Inhibition (The PEACE study design)

Marc A. Pfeffer; Michael Domanski; Yves Rosenberg; Joel Verter; Nancy Geller; Paul Albert; Judith Hsia; Eugene Braunwald

doi:10.1016/S0002-9149(98)00488-3

Prevention of Events with Angiotensin-Converting Enzyme Inhibition (The PEACE study design)

Marc A. Pfeffer
, Michael Domanski
, Yves Rosenberg
, Joel Verter
, Nancy Geller
, Paul Albert
, Judith Hsia
, Eugene Braunwald

Research output: Contribution to journal › Article › peer-review

72 Scopus citations

Abstract

The Prevention of Events with Angiotensin-Converting Enzyme Inhibition (PEACE) trial is an 8,100 patient, randomized, double-blind, placebo- controlled trial designed to determine the usefulness of angiotensin- converting enzyme (ACE) inhibitors in treating coronary patients with preserved left ventricular ejection fraction. The hypothesis being tested in this trial is that patients with coronary disease and ejection fraction ≤40% who are treated with ACE inhibitors will experience a reduction in the incidence of cardiovascular death, nonfatal myocardial infarction, or a revascularization procedure compared with patients treated with conventional therapy. The design of the PEACE trial is described herein.

Original language	English
Pages (from-to)	25-30
Number of pages	6
Journal	American Journal of Cardiology
Volume	82
Issue number	3 A
DOIs	https://doi.org/10.1016/S0002-9149(98)00488-3
State	Published - 6 Aug 1998
Externally published	Yes

Access to Document

10.1016/S0002-9149(98)00488-3

Cite this

@article{3f99f6a931a3473fbf840661d1e44679,

title = "Prevention of Events with Angiotensin-Converting Enzyme Inhibition (The PEACE study design)",

abstract = "The Prevention of Events with Angiotensin-Converting Enzyme Inhibition (PEACE) trial is an 8,100 patient, randomized, double-blind, placebo- controlled trial designed to determine the usefulness of angiotensin- converting enzyme (ACE) inhibitors in treating coronary patients with preserved left ventricular ejection fraction. The hypothesis being tested in this trial is that patients with coronary disease and ejection fraction ≤40\% who are treated with ACE inhibitors will experience a reduction in the incidence of cardiovascular death, nonfatal myocardial infarction, or a revascularization procedure compared with patients treated with conventional therapy. The design of the PEACE trial is described herein.",

author = "Pfeffer, \{Marc A.\} and Michael Domanski and Yves Rosenberg and Joel Verter and Nancy Geller and Paul Albert and Judith Hsia and Eugene Braunwald",

note = "Funding Information: PEACE is supported by a grant from the National Heart, Lung, and Blood Institute of the US National Institutes of Health; drug supply and distribution is provided by a grant from Knoll. ",

year = "1998",

month = aug,

day = "6",

doi = "10.1016/S0002-9149(98)00488-3",

language = "English",

volume = "82",

pages = "25--30",

journal = "American Journal of Cardiology",

issn = "0002-9149",

publisher = "Elsevier Inc.",

number = "3 A",

}

TY - JOUR

T1 - Prevention of Events with Angiotensin-Converting Enzyme Inhibition (The PEACE study design)

AU - Pfeffer, Marc A.

AU - Domanski, Michael

AU - Rosenberg, Yves

AU - Verter, Joel

AU - Geller, Nancy

AU - Albert, Paul

AU - Hsia, Judith

AU - Braunwald, Eugene

N1 - Funding Information: PEACE is supported by a grant from the National Heart, Lung, and Blood Institute of the US National Institutes of Health; drug supply and distribution is provided by a grant from Knoll.

PY - 1998/8/6

Y1 - 1998/8/6

N2 - The Prevention of Events with Angiotensin-Converting Enzyme Inhibition (PEACE) trial is an 8,100 patient, randomized, double-blind, placebo- controlled trial designed to determine the usefulness of angiotensin- converting enzyme (ACE) inhibitors in treating coronary patients with preserved left ventricular ejection fraction. The hypothesis being tested in this trial is that patients with coronary disease and ejection fraction ≤40% who are treated with ACE inhibitors will experience a reduction in the incidence of cardiovascular death, nonfatal myocardial infarction, or a revascularization procedure compared with patients treated with conventional therapy. The design of the PEACE trial is described herein.

AB - The Prevention of Events with Angiotensin-Converting Enzyme Inhibition (PEACE) trial is an 8,100 patient, randomized, double-blind, placebo- controlled trial designed to determine the usefulness of angiotensin- converting enzyme (ACE) inhibitors in treating coronary patients with preserved left ventricular ejection fraction. The hypothesis being tested in this trial is that patients with coronary disease and ejection fraction ≤40% who are treated with ACE inhibitors will experience a reduction in the incidence of cardiovascular death, nonfatal myocardial infarction, or a revascularization procedure compared with patients treated with conventional therapy. The design of the PEACE trial is described herein.

UR - https://www.scopus.com/pages/publications/0031722541

U2 - 10.1016/S0002-9149(98)00488-3

DO - 10.1016/S0002-9149(98)00488-3

M3 - Article

C2 - 9719019

AN - SCOPUS:0031722541

SN - 0002-9149

VL - 82

SP - 25

EP - 30

JO - American Journal of Cardiology

JF - American Journal of Cardiology

IS - 3 A

ER -

Prevention of Events with Angiotensin-Converting Enzyme Inhibition (The PEACE study design)

Abstract

Access to Document

Fingerprint

Cite this